Outline in brief the main aim of safety pharmacology, and the differences between safety predictions driven by in vitriol mechanistic profiling vs in viva toxicity per-clinical testing describe strengths and limitations of each approach
Present the data from the analysis, appropriately labelled with descriptive legends and some descriptive text.
The modulation of some drug targets is highly predictive of clinical toxicity. Using the safety pharmacology concepts taught in the lectures, discuss why one compound will likely be safer than the other. Support your prediction using published literature on the two drugs.